NasdaqGS - Nasdaq Real Time Price USD

Viatris Inc. (VTRS)

Compare
11.59 +0.02 (+0.13%)
As of 10:49 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Scott Andrew Smith CEO & Director 5.07M -- 1962
Mr. Brian S. Roman Chief Legal Officer 2.51M -- 1971
Ms. Theodora Mistras Chief Financial Officer -- -- 1982
Mr. Paul B. Campbell Chief Accounting Officer, Senior VP & Corporate Controller -- -- 1968
Mr. Ramkumar V. Rayapureddy Chief Information Officer -- -- --
Mr. Andrew Enrietti Chief People Officer -- -- --
Mr. Menassie Taddese M.B.A. President of Emerging Markets -- -- 1970
Mr. Derek Glover Chief Quality Officer -- -- --
Ms. Lara Ramsburg Chief Corporate Affairs Officer -- -- --
Dr. Jeffrey Nau MMS, Ph.D. President of Viatris Eye Care Division -- -- 1976

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800 https://www.viatris.com
Sector:?
Healthcare
Full Time Employees:?
33,000

Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Corporate Governance

Viatris Inc.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 1:30 PM UTC

Viatris Inc. Earnings Date

Recent Events

September 27, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 13, 2024 at 12:00 AM UTC

Dividend Date

September 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 23, 2024 at 12:00 AM UTC

Ex-Dividend Date

August 8, 2024 at 12:30 PM UTC

Q2 2024 Earnings Call

August 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 26, 2024 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

Related Tickers